Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Metastatic colorectal cancer (mCRC) presents a significant clinical challenge with poor survival rates.
• Early diagnosis of mCRC is often delayed, contributing to advanced disease at presentation.
• Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer progression.

Purpose of the Study:

• To investigate the prognostic significance of lncRNAs in mCRC.
• To explore the functional role of PCAT6 in colorectal cancer metastasis.

Main Methods:

• Analysis of The Cancer Genome Atlas (TCGA) data for PCAT6 expression and survival correlation.
• Validation of PCAT6 expression in patient samples from Fudan University Shanghai Cancer Center.
• In vitro studies using cell lines and in vivo studies using xenograft mouse models to assess PCAT6 function.
• Functional assays to evaluate the impact of PCAT6 knockdown on epithelial-mesenchymal transition (EMT) and stemness.

Main Results:

• Elevated PCAT6 expression was independently associated with unfavorable survival outcomes in mCRC patients.
• PCAT6 knockdown significantly impeded the metastatic phenotype of colorectal cancer cells.
• Suppression of EMT and stemness was observed upon PCAT6 knockdown, indicating its role in promoting metastasis.

Conclusions:

• PCAT6 is a significant factor in mCRC progression and metastasis.
• PCAT6 holds potential as a prognostic biomarker for patients with metastatic colorectal cancer.
• Targeting PCAT6 may offer a therapeutic strategy to inhibit mCRC metastasis.